BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:21 2024-04-26 am EDT			5-day change	1st Jan Change
0.65 ^EUR	-4.41%		-1.52%	-39.81%

Apr. 15	BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	CI
Apr. 03	BenevolentAI Founder Reportedly Calls for Board Revamp	MT

BenevolentAI : Benevolent AI, - Publication of 2023 Annual Report and 2024 AGM Notice

March 20, 2024 at 05:56 am EDT

Benevolent AI

Benevolent AI

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date19 mar 2024 - 19:18

Statutory nameBenevolent AI

TitlePublication of 2023 Annual Report and 2024 AGM Notice

Previous result

Next result

Related downloads

202403190000000024_BAI PR - Publication of 2023 Annual Report and 2024 AGM Notice FINAL.pdf(opens in a new window)

Date last update: 20 March 2024

Attachments

Original Link
Permalink

Disclaimer

BenevolentAi SA published this content on 19 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 March 2024 09:55:00 UTC.

Latest news about BenevolentAI

BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	Apr. 15	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
Kenneth Mulvany Sends a Letter to Benovelent AI	Apr. 02	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	Mar. 25	CI
BenevolentAI Announces Executive Changes	Mar. 20	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member	Jan. 24	CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer	Jan. 24	CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO	Jan. 22	AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	23-09-26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
BenevolentAI S.A. Announces Executive Changes	23-09-21	CI
BenevolentAI S.A. Announces Management Changes	23-09-21	CI
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery	23-09-20	DJ
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	23-09-20	MT
BenevolentAI Signs Strategic Collaboration with Merck	23-09-20	CI
BenevolentAI Appoints Chief Revenue Officer	23-09-18	MT
BenevolentAI Appoints Catherine Isted as Chief Financial Officer	23-09-11	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	23-08-31	CI
BenevolentAI Announces Retirement of Jackie Hunter as Non-Executive Director	23-06-21	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	23-06-05	CI
BenevolentAI Announces New Preclinical Data on Ai-Generated Target Identified in Their Ongoing Collaboration with Astrazeneca	23-05-31	CI
Benevolentai S.A. Launches New Suite of Products	23-05-24	CI

Chart BenevolentAI

Duration

Period

More charts

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5571 GBP

Average target price

1.632 GBP

Spread / Average Target

+192.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-39.81%	84.62M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research